1. Home
  2. MKZR vs PCSA Comparison

MKZR vs PCSA Comparison

Compare MKZR & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacKenzie Realty Capital Inc.

MKZR

MacKenzie Realty Capital Inc.

HOLD

Current Price

$3.75

Market Cap

7.6M

Sector

N/A

ML Signal

HOLD

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$3.82

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKZR
PCSA
Founded
2012
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
8.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MKZR
PCSA
Price
$3.75
$3.82
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
41.8K
2.0M
Earning Date
11-14-2025
11-06-2025
Dividend Yield
26.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,994,778.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.63
N/A
52 Week Low
$3.26
$2.74
52 Week High
$50.00
$27.00

Technical Indicators

Market Signals
Indicator
MKZR
PCSA
Relative Strength Index (RSI) 41.73 67.06
Support Level $3.65 $0.11
Resistance Level $5.00 $8.88
Average True Range (ATR) 0.44 0.52
MACD 0.03 0.46
Stochastic Oscillator 19.77 42.63

Price Performance

Historical Comparison
MKZR
PCSA

About MKZR MacKenzie Realty Capital Inc.

Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Share on Social Networks: